(Q46220335)

20 December 2017

title

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus (English)

1 reference

20 December 2017

0 references

1 reference

1 reference

Prajakti A Kothare

1

1 reference

20 December 2017

Helle Linnebjerg

2

1 reference

20 December 2017

Yoshitaka Isaka

3

1 reference

20 December 2017

Kazunori Uenaka

4

1 reference

20 December 2017

Ayuko Yamamura

5

1 reference

20 December 2017

Kwee Poo Yeo

6

1 reference

20 December 2017

Amparo de la Peña

7

1 reference

20 December 2017

Choo Hua Teng

8

1 reference

20 December 2017

Kenneth Mace

9

1 reference

20 December 2017

Mark Fineman

10

1 reference

20 December 2017

Hirofumi Shigeta

11

1 reference

20 December 2017

Yukikuni Sakata

12

1 reference

20 December 2017

Shin Irie

13

1 reference

20 December 2017

publication date

1 December 2008

1 reference

20 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

20 December 2017

volume

48

1 reference

20 December 2017

issue

12

1 reference

20 December 2017

page(s)

1389-1399

1 reference

20 December 2017

https://api.crossref.org/works/10.1177%2F0091270008323750

1 reference

21 January 2018

Diabetes trends in Japan

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Factors responsible for glucose intolerance in Japanese subjects with impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Diabetes trends in the U.S.: 1990-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Confidence interval criteria for assessment of dose proportionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Investigation of exenatide elimination and its in vivo and in vitro degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

Triggering and amplifying pathways of regulation of insulin secretion by glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008323750

21 January 2018

Identifiers

DOI

10.1177/0091270008323750

1 reference

20 December 2017

1 reference

20 December 2017